Biotech
Wednesday, February 21st, 2024 3:34 pm EDT
Key Points
- The launch of the Alzheimer’s drug Leqembi, the first to slow the disease’s progression in the U.S., is facing a slow start, despite rising demand from Biogen and Eisai.
- Biogen is banking on Leqembi to drive growth amidst declining sales of its multiple sclerosis therapies, with hopes of treating 10,000 patients by March. However, only about 2,000 patients are currently on Leqembi, presenting challenges in meeting the target.
- Challenges include the complex process patients must undergo to receive the drug, logistical hurdles in accommodating patient flow, and issues related to MRI monitoring for potential side effects. Additionally, Biogen and Eisai are working toward FDA approval of an injectable version of Leqembi to enhance convenience and uptake.
The launch of the Alzheimer’s drug Leqembi by Biogen and Eisai has faced a slow start despite increasing demand. As the first drug approved to slow Alzheimer’s progression in the U.S., Leqembi signifies a significant advancement for over 6 million older Americans afflicted with the disease. Biogen, in particular, sees Leqembi as crucial for driving growth amidst declining sales of its multiple sclerosis therapies. However, only about 2,000 patients are currently on Leqembi, making the target of 10,000 treated patients by March challenging. Challenges include the complex process patients must undergo to receive the drug, including confirmation of Alzheimer’s stage and beta-amyloid presence, as well as MRI monitoring for potential side effects. While demand is high, logistical hurdles remain, impacting the drug’s uptake. Despite initial setbacks, Biogen and Eisai are exploring an injectable version of Leqembi for easier administration. Meanwhile, Apple’s new mixed reality headset, the Vision Pro, has garnered attention but also caused discomfort for some users, prompting Apple to provide tips for managing motion sickness. Experts suggest moderation and proper setup to alleviate symptoms, emphasizing the importance of listening to one’s body when using immersive technology.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/02/20/healthy-returns-alzheimers-drug-leqembi-launch-apple-vision-pro-nausea.html
